dc.creator | Taştemur, Şeyma | |
dc.creator | Ataseven, Hilmi | |
dc.date.accessioned | 2020-08-03T19:44:28Z | |
dc.date.accessioned | 2022-09-23T18:49:34Z | |
dc.date.available | 2020-08-03T19:44:28Z | |
dc.date.available | 2022-09-23T18:49:34Z | |
dc.date.created | 2020-08-03T19:44:28Z | |
dc.identifier | 0306-9877 | |
dc.identifier | https://doi.org/10.1016/j.mehy.2020.110018 | |
dc.identifier | http://hdl.handle.net/20.500.12010/11560 | |
dc.identifier | https://doi.org/10.1016/j.mehy.2020.110018 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3508079 | |
dc.description.abstract | Coronaviruses (CoV), discovered after 1960, caused human life-threatening outbreaks.
SARS-CoV2, which appeared in Wuhan, China in December 2019, causing Severe Acute
Respiratory Syndrome and has different features than other coronaviruses, has been determined
and the disease caused by the virus has been called "Coronavirus Disease-2019" (COVID-19).
This disease activates both the natural and acquired immune system. The cytokin storm, in
which blood levels of proinflammatory cytokines are detected excessively high is developing
and the uncontrolled inflammatory response causes local and systemic tissue damages.
Although a spesific drug has not been found yet, the medications currently in use for other
indications, whose pharmacokinetic- pharmacodynamic properties and toxic doses are already
known; are included in the treatment practice of COVID-19. These drugs affect the entry of the
virus into the cell and its intracellular distribution. They also have anti-inflammatory and
immunomodulating effects too. Therefore, we think that Proton Pump Inhibitors (PPI’s) with
similar mechanisms of action may also be involved in COVID-19 treatment and prophylaxis. | |
dc.publisher | Medical Hypotheses | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.source | reponame:Expeditio Repositorio Institucional UJTL | |
dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | |
dc.subject | COVID-19 | |
dc.subject | SARS-CoV2 | |
dc.subject | Proton Pump Inhibitors | |
dc.subject | Treatment | |
dc.title | Is it possible to use proton pump inhibitors in COVID-19 treatment and pro‐ phylaxis? | |